Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Macrogenics Inc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 4.04 · gapped above the open, then crossed back over prior close. High/low 4.09 at 1:00 pm ET, 4.03 at 10:15 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We also have an agreement with Incyte under which we are entitled to manufacture a portion of Incyte's global commercial supply of retifanlimab (Incyte Commercial Supply Agreement).”
FILING10-K0001125345-26-000017cik 0001125345
“In November 2024, we sold global rights to MARGENZA to TerSera Therapeutics, LLC (TerSera) for an upfront payment of $40.0 million, and accordingly, no longer have product sales;”
FILING10-K0001125345-26-000017cik 0001125345
“In 2023, we entered into an agreement with Emergent BioSolutions (Emergent) to provide development and manufacturing services to produce certain Emergent bulk drug substances.”
FILING10-K0001125345-26-000017cik 0001125345
“As part of the Gilead Agreement, Gilead paid us a non-refundable upfront payment of $60.0 million and we are eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones, assuming Gilead exercises the CD123 Option and Research Program Option, successfully develops and commercializes MGD024 or other CD123 products developed under the agreement, and products result from the two additional research programs .”
FILING10-K0001125345-26-000017cik 0001125345
“In 2018, we entered into an asset purchase agreement (Provention APA) with Provention Bio, Inc., subsequently acquired by Sanofi S.A. (Sanofi), pursuant to which they acquired our interest in teplizumab, a mAb we had been developing for the treatment of type 1 diabetes.”
FILING10-K0001125345-26-000017cik 0001125345
“In June 2025, we entered into a Purchase and Sale Agreement (Royalty Purchase Agreement) with Sagard, pursuant to which we sold to Sagard our right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) occurring on and after July 1, 2025 under our Incyte License Agreement, dated as of October 24, 2017, as amended.”
FILING10-K0001125345-26-000017cik 0001125345
“The underlying ADC technology was licensed from Byondis B.V. (Byondis).”
FILING10-K0001125345-26-000017cik 0001125345
“Selling, general and administrative expense also includes legal and professional fees and included costs incurred under the arrangement with our commercialization partner, Eversana Life Science Services, LLC in 2023 and 2024.”
FILING10-K0001125345-26-000017cik 0001125345
“In November 2024, we paid an $8.0 million amendment fee to Eversana Life Sciences Services, LLC (Eversana), our former partner that had previously commercialized MARGENZA.”
FILING10-K0001125345-26-000017cik 0001125345
“We also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates.”
FILING10-K0001125345-26-000017cik 0001125345
“In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.”
FILING10-K0001125345-26-000017cik 0001125345
“In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.”
FILING10-K0001125345-26-000017cik 0001125345
“We also rely on our licensees and contract manufacturers, including, Synaffix, Sterling and Millipore Sigma, for producing components of our ADC candidates.”
FILING10-K0001125345-26-000017cik 0001125345
“In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily PCI Pharma Services (formerly known as Ajinomoto Bio-Pharma Services), Symbiosis, and Simtra BioPharma Solutions, to fulfill our fill-finish needs for our current and future product candidates.”
FILING10-K0001125345-26-000017cik 0001125345
“Certain of our ADC products in development incorporate technology developed by our collaboration partners, including: MGC026 and MGC028 (incorporate Hydraspace ® , GlycoConnect™ ® , and toxSYN® technology developed by our collaboration partner, Synaffix).”
FILING10-K0001125345-26-000017cik 0001125345
“This cleavable linker-payload is based on exatecan, a clinically validated and potent camptothecin, and is site-specifically conjugated using the GlycoConnect® technology developed by our collaboration partner, Synaffix B.V., a Lonza company (Synaffix).”
FILING10-K0001125345-26-000017cik 0001125345
“The decrease of $32.7 million in revenue from collaborative and other agreements for the year ended December 31, 2025 compared to the year ended December 31, 2024 was primarily due to $100.0 million recognized from milestones under the Incyte License Agreement in 2024 compared to $50.0 million recognized from milestones under the Provention (Sanofi) Asset Purchase Agreement and $25.0 million from the Gilead Agreement in 2025.”
FILING10-K0001125345-26-000017cik 0001125345
Watchlist prices, news filtered to it, and its next report on your desk.
Macrogenics Inc has 10 disclosed suppliers and 7 disclosed customers. Each one is named in an SEC filing, either Macrogenics Inc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
MGNX (Macrogenics Inc) has 10 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: EBS −0.16%, in healthcare.